RxDoctor Payments DataLook up a doctor →

Ramana Rao, MD

Critical Care Medicine · Albany, GANPI 1215920491

Payments from drug & device makers

$13,087in general payments, 2019–2025

Across 461 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$2K
  • AstraZeneca$956
  • Boehringer Ingelheim$943
  • Insmed, Inc.$742
  • Actelion Pharmaceuticals US, Inc.$637
  • plus $5K from 41 others

What the payments were for

  • Travel & lodging$4553%
  • Food & beverage$9,84675%
  • Education$2,78521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,087 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$44,180
Medicare patients
274
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate49$669,606
OpsumitMacitentan36$457,378
UptraviSelexipag17$384,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter210$136,253
WakixPitolisant Hcl15$107,027
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$41,988
Pirfenidone15$32,853
Combivent RespimatIpratropium/Albuterol Sulfate22$12,531
Spiriva RespimatTiotropium Bromide18$9,294
SymbicortBudesonide/Formoterol Fumarate28$8,240
Breo ElliptaFluticasone/Vilanterol20$7,343
Albuterol Sulfate HfaAlbuterol Sulfate219$4,892
Methylprednisolone64$405
Prednisone62$375
Montelukast Sodium39$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$637$841,88953 claims
Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat$943$691,43289 claims
GSKTrelegy Ellipta, Breo Ellipta$1,967$143,596230 claims
Harmony Biosciences LLCWakix$115$107,02715 claims
AstraZenecaBreztri Aerosphere, Symbicort$956$50,22989 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →